Nasopharyngeal carcinoma: A review

Seminars in Diagnostic Pathology

Volumn 32, Issue 1, 2015, Pages 54-73

  Petersson, Fredrik ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Carcinoma; Nasopharyngeal carcinoma; Nasopharynx; Pathology

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADJUVANT THERAPY; BONE NECROSIS; BRAIN NECROSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CAROTID ARTERY OBSTRUCTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE PARALYSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FAMILIAL CANCER; FIBROSIS; GEOGRAPHIC DISTRIBUTION; HEARING IMPAIRMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; METASTASIS; MOLECULAR GENETICS; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PAPILLOMAVIRUS INFECTION; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT INDICATION; EPSTEIN BARR VIRUS; ISOLATION AND PURIFICATION; NASOPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; VIROLOGY;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84925304110     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2015.02.021     Document Type: Review

References (259)

1. Jackson C. Primary carcinoma of the nasopharynx. A table of cases. J Am Med Assoc 1901, 37371-37377.
2. New G. Syndrome of malignant tumors of the nasopharynx, a report of seventy nine cases. J Am Med Assoc 1922, 10-14.
3. Digby Kea Nasopharyngeal carcinoma. Br J Surg 1941, 517-537.
4. Chan J.K.C., Pilch B.Z., Bray F., et al. Nasopharyngeal carcinoma. WHO Classification of Tumours 2005, 85-97. WHO/IARC Press, Lyon. L. Barnes, J.W. Eveson (Eds.).
5. Shanmugaratnam K. Nasopharyngeal Origin and Structure in Cancer of the Nasopharynx 1967, 147-152. Munksgaard, Copenhagen.
6. Yeh S. Histology of nasopharyngeal cancer. Cancer of the Nasopharynx 1967, 147-152. Munksgaard, Copenhagen.
7. Lo K.W., Cheung S.T., Leung S.F., et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996, 56:2721-2725.
8. Chan A.S., To K.F., Lo K.W., et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 2000, 60:5365-5370.
9. Lo K.W., Teo P.M., Hui A.B., et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 2000, 60:3348-3353.
10. Lo K.W., Kwong J., Hui A.B., et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001, 61:3877-3881.
11. Chan A.S., To K.F., Lo K.W., et al. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int J Cancer 2002, 102:300-303.
12. Pathmanathan R., Prasad U., Sadler R., Flynn K., Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995, 333:693-698.
13. Yeung W.M., Zong Y.S., Chiu C.T., et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 1993, 53:746-750.
14. Lo K.W., To K.F., Huang D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5:423-428.
15. Ho J.H. Nasopharyngeal carcinoma (NPC). Adv Cancer Res 1972, 15:57-92.
16. Lu S.J., Day N.E., Degos L., et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 1990, 346:470-471.
17. Goldsmith D.B., West T.M., Morton R.H.L. A associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis. Clin Otolaryngol Allied Sci 2002, 27:61-67.
18. Hu S.P., Day N.E., Li D.R., et al. Further evidence for an HLA-related recessive mutation in nasopharyngeal carcinoma among the Chinese. Br J Cancer 2005, 92:967-970.
19. Bei J.X., Li Y., Jia W.H., et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010, 42:599-603.
20. Tse K.P., Su W.H., Chang K.P., et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 2009, 85:194-203.
21. Hildesheim A., Apple R.J., Chen C.J., et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 2002, 94:1780-1789.
22. Hildesheim A., Chen C.J., Caporaso N.E., et al. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev 1995, 4:607-610.
23. Hildesheim A., Anderson L.M., Chen C.J., et al. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 1997, 89:1207-1212.
24. Feng B.J., Huang W., Shugart Y.Y., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002, 31:395-399.
25. Xiong W., Zeng Z.Y., Xia J.H., et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004, 64:1972-1974.
26. Yu M.C., Ho J.H., Ross R.K., Henderson B.E. Nasopharyngeal carcinoma in Chinese-salted fish or inhaled smoke?. Prev Med 1981, 10:15-24.
27. Yu M.C., Ho J.H., Lai S.H., Henderson B.E. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res 1986, 46:956-961.
28. Armstrong R.W., Armstrong M.J., Yu M.C., Henderson B.E. Salted fish and inhalants as risk factors for nasopharyngeal carcinoma in Malaysian Chinese. Cancer Res 1983, 43:2967-2970.
29. Armstrong R.W., Imrey P.B., Lye M.S., Armstrong M.J., Yu M.C., Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. Int J Cancer 1998, 77:228-235.
30. Yu M.C., Mo C.C., Chong W.X., Yeh F.S., Henderson BE. Preserved foods and nasopharyngeal carcinoma: a case-control study in Guangxi, China. Cancer Res 1988, 48:1954-1959.
31. Yu M.C., Huang T.B., Henderson B.E. Diet and nasopharyngeal carcinoma: a case-control study in Guangzhou, China. Int J Cancer 1989, 43:1077-1082.
32. Ning J.P., Yu M.C., Wang Q.S., Henderson B.E., et al. Consumption of salted fish and other risk factors for nasopharyngeal carcinoma (NPC) in Tianjin, a low-risk region for NPC in the People[U+05F3]s Republic of China. J Natl Cancer Inst 1990, 82:291-296.
33. Ho J.H., Huang D.P., Fong Y.Y. Salted fish and nasopharyngeal carcinoma in southern Chinese. Lancet 1978, 2:626.
34. Huang D.P., Ho J.H., Saw D., Teoh T.B. Carcinoma of the nasal and paranasal regions in rats fed Cantonese salted marine fish. IARC Sci Publ 1978, 315-328.
35. Huang D.P., Ho J.H., Webb K.S., Wood B.J., Gough T.A. Volatile nitrosamines in salt-preserved fish before and after cooking. Food Cosmet Toxicol 1981, 19:167-171.
36. Zou X.N., Lu S.H., Liu B. Volatile N-nitrosamines and their precursors in Chinese salted fish-a possible etiological factor for NPC in china. Int J Cancer 1994, 59:155-158.
37. Shao Y.M., Poirier S., Ohshima H., et al. Epstein-Barr virus activation in Raji cells by extracts of preserved food from high risk areas for nasopharyngeal carcinoma. Carcinogenesis 1988, 9:1455-1457.
38. Huang D.P., Ho J.H., Gough T.A. Analysis for volatile nitrosamines in salt-preserved foodstuffs traditionally consumed by southern Chinese. IARC Sci Publ 1978, 309-314.
39. Armstrong R.W., Imrey P.B., Lye M.S., Armstrong M.J., Yu M.C., Sani S., et al. Nasopharyngeal carcinoma in Malaysian Chinese: occupational exposures to particles, formaldehyde and heat. Int J Epidemiol 2000, 29:991-998.
40. Yu M.C., Garabrant D.H., Huang T.B., Henderson B.E. Occupational and other non-dietary risk factors for nasopharyngeal carcinoma in Guangzhou, China. Int J Cancer 1990, 45:1033-1039.
41. Schoental R., Gibbard S. Carcinogens in Chinese incense smoke. Nature 1967, 216:612.
42. Yang C.R., Lin T.C., Chang F.H. Particle size distribution and PAH concentrations of incense smoke in a combustion chamber. Environ Pollut 2007, 145:606-615.
43. Huang D.P., Lo K.W., van Hasselt C.A., et al. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 1994, 54:4003-4006.
44. Lo K., Tsao S., Leung S., Choi P., Lee J., Huang D. Detailed deletion mapping on the short arm of chromosome-3 in nasopharyngeal carcinomas. Int J Oncol 1994, 4:1359-1364.
45. Hui A.B., Lo K.W., Leung S.F., et al. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 1999, 82:498-503.
46. Shebl F.M., Bhatia K., Engels E.A. Salivary gland and nasopharyngeal cancers in individuals with acquired immunodeficiency syndrome in United States. Int J Cancer 2010, 126:2503-2508.
47. Shi W., Bastianutto C., Li A., et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 2006, 119:2467-2475.
48. Zeng Z.Y., Zhou Y.H., Zhang W.L., et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol 2007, 38:120-133.
49. Morrison J.A., Gulley M.L., Pathmanathan R., Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004, 64:5251-5260.
50. Mazieres J., He B., You L., Xu Z., Jablons D.M. Wnt signaling in lung cancer. Cancer Lett 2005, 222:1-10.
51. Yip K.W., Shi W., Pintilie M., et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006, 12:5726-5732.
52. Fan S.Q., Ma J., Zhou J., et al. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol 2006, 37:593-605.
53. Lu Q.L., Elia G., Lucas S., Thomas J.A. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993, 53:29-35.
54. Chou C.C., Chou M.J., Tzen C.Y. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 2009, 26:322-326.
55. Or Y.Y., Hui A.B., To K.F., Lam C.N., Lo K.W. PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 2006, 118:1065-1067.
56. Fendri A., Khabir A., Mnejja W., et al. PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci 2009, 100:2034-2039.
57. Mainou B.A., Everly D.N., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 2005, 24:6917-6924.
58. Xueguan L., Xiaoshen W., Yongsheng Z., Chaosu H., Chunying S., Yan F. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol) 2008, 20:606-612.
59. Chen M.K., Lee H.S., Chang J.H., Chang CC. Expression of p53 protein and primary tumour volume in patients with nasopharyngeal carcinoma. J Otolaryngol 2004, 33:304-307.
60. Wu H.C., Lu T.Y., Lee J.J., et al. MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab Invest 2004, 84:1547-1556.
61. Burgos J.S. Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. Med Oncol 2005, 22:113-121.
62. Sheu L.F., Chen A., Lee H.S., Hsu H.Y., Yu DS. Cooperative interactions among p53, bcl-2 and Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells. Pathol Int 2004, 54:475-485.
63. Kwong J., Lo K.W., To K.F., Teo P.M., Johnson P.J., Huang D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002, 8:131-137.
64. Crook T., Nicholls J.M., Brooks L., O'Nions J., Allday M.J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?. Oncogene 2000, 19:3439-3444.
65. Lo K.W., Huang D.P., Lau K.M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995, 55:2039-2043.
66. Hwang C.F., Cho C.L., Huang C.C., et al. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 2002, 13:1246-1251.
67. Makitie A.A., MacMillan C., Ho J., et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003, 9:2177-2184.
68. Hwang C.F., Su C.Y., Huang S.C., et al. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Lett 2003, 189:231-236.
69. Baba Y., Tsukuda M., Mochimatsu I., et al. Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. Cancer Detect Prev 2001, 25:414-419.
70. Hui A.B., Or Y.Y., Takano H., et al. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 2005, 65:8125-8133.
71. Yu Y., Dong W., Li X., Yu E., Zhou X., Li S. Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003, 129:1322-1326.
72. al PDe. Cancer incidence in five continents. IARC. 1997;814-815.
73. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
74. Ho J.H. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978, 4:182-198.
75. Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res 1974, 34:1189-1191.
76. Flores A.D., Dickson R.I., Riding K., Coy P. Cancer of the nasopharynx in British Columbia. Am J Clin Oncol 1986, 9:281-291.
77. Hamilton S.N., Ho C., Laskin J., Zhai Y., Mak P., Wu J. Asian versus Non-Asian outcomes in nasopharyngeal carcinoma: a North American population-based analysis. Am J Clin Oncol 2014, [Epub ahead of print].
78. Li C.C., Yu M.C., Henderson B.E. Some epidemiologic observations of nasopharyngeal carcinoma in Guangdong, People[U+05F3]s Republic of China. Natl Cancer Inst Monogr 1985, 69:49-52.
79. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:421-429.
80. Yu W.M., Hussain S.S. Incidence of nasopharyngeal carcinoma in Chinese immigrants, compared with Chinese in China and South East Asia: review. J Laryngol Otol 2009, 123:1067-1074.
81. Geser A., Charnay N., Day N.E., de-The G., Ho H.C. Environmental factors in the etiology of nasopharyngeal carcinoma: report on a case-control study in Hong Kong. IARC Sci Publ 1978, 213-229.
82. Bergin M., Bird P., Cowan I., Pearson J.F. Exploring the critical distance and position relationships between the Eustachian tube and the internal carotid artery. Otol Neurotol 2010, 31:1511-1515.
83. Hoe J. CT of nasopharyngeal carcinoma: significance of widening of the preoccipital soft tissue on axial scans. Am J Roentgenol 1989, 153:867-872.
84. Hoe J.W. Computed tomography of nasopharyngeal carcinoma. A review of CT appearances in 56 patients. Eur J Radiol 1989, 9:83-90.
85. Sham J.S., Wei W.I., Zong Y.S., et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 1990, 335:371-374.
86. Loh L.E., Chee T.S., John A.B. The anatomy of the Fossa of Rosenmuller-its possible influence on the detection of occult nasopharyngeal carcinoma. Singapore Med J 1991, 32:154-155.
87. Hsu M.M., Tu S.M. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983, 52:362-368.
88. Vokes E.E., Liebowitz D.N., Weichselbaum R.R. Nasopharyngeal carcinoma. Lancet 1997, 350:1087-1091.
89. Lee A.W., Foo W., Law S.C., et al. Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis. Hong Kong Med J 1997, 3:355-361.
90. Teo P., Yu P., Lee W.Y., et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 1996, 36:291-304.
91. Sham J.S., Poon Y.F., Wei W.I., Choy D. Nasopharyngeal carcinoma in young patients. Cancer 1990, 65:2606-2610.
92. Zhang G.Z., Liu Z.L., Gong J.S., Cheng Z.Q., Ke C. Cystic metastatic nasopharyngeal carcinoma presenting as branchial cleft cyst: report of two cases and review of the literature. J Oral Maxillofac Surg 2014, 72:2366-2374.
93. Thompson L.D., Heffner D.K. The clinical importance of cystic squamous cell carcinomas in the neck: a study of 136 cases. Cancer 1998, 82:944-956.
94. Regauer S., Mannweiler S., Anderhuber W., et al. Cystic lymph node metastases of squamous cell carcinoma of Waldeyer[U+05F3]s ring origin. Br J Cancer 1999, 79:1437-1442.
95. Loh K.S., Petersson F. Nonexophytic nasopharyngeal carcinoma: high frequency of advanced lymph node and distant metastasis. Otolaryngol Head Neck Surg 2011, 145:594-598.
96. Yeh S. A histological classification of carcinomas of the nasopharynx with a critical review as to the existence of lymphoepitheliomas. Cancer 1962, 15:895-920.
97. Liang P., Chen C., Chu C., Hu Y., Chu H., Tsung Y. The histopathologic classification, biologic characteristics and histiogenesis of nasopharyngeal carcinomas. Chin Med J 1962, 81:629-658.
98. Shanmugaratnam K., Muir C. Cancer of the Nasopharynx 1967, Munksgaard, Copenhagen.
99. Shanmugaratnam K. The Pathology of Nasopharyngeal Carcinoma: a Review 1972, 239-248. IARC, Lyon.
100. Petersson F., Vijayadwaja D., Loh K.S., Tan K.B. Reticular and myxoid non-keratinizing nasopharyngeal carcinoma: an unusual case mimicking a salivary gland carcinoma. Head Neck Pathol 2014, 8:364-368.
101. Petersson F., Loh K.S., Lim D. Paucilymphoid non-keratinizing nasopharyngeal carcinoma with prominent stromal desmoplasia-an unusual case reported with brief comments on uncommon histological variants. Int J Clin Exp Pathol 2011, 4:410-415.
102. Wain S.L., Kier R., Vollmer R.T., Bossen E.H. Basaloid-squamous carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. Hum Pathol 1986, 17:1158-1166.
103. Wan S.K., Chan J.K., Lau W.H., Yip T.T. Basaloid-squamous carcinoma of the nasopharynx. An Epstein-Barr virus-associated neoplasm compared with morphologically identical tumors occurring in other sites. Cancer 1995, 76:1689-1693.
104. Pan J., Xu Y., Qiu S., et al. A comparison between the Chinese 2008 and the 7th edition AJCC staging systems for nasopharyngeal carcinoma. Am J Clin Oncol 2013, [Epub ahead of print].
105. Sham J.S., Choy D. Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. Br J Radiol 1990, 63:51-58.
106. Perez C.A., Devineni V.R., Marcial-Vega V., Marks J.E., Simpson J.R., Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992, 23:271-280.
107. Sze W.M., Lee A.W., Yau T.K., et al. Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int J Radiat Oncol Biol Phys 2004, 59:21-27.
108. Chang C.C., Chen M.K., Liu M.T., Wu H.K. The effect of primary tumor volumes in advanced T-staged nasopharyngeal tumors. Head Neck 2002, 24:940-946.
109. Lo Y.M. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann N Y Acad Sci 2001, 945:68-72.
110. Levine P.H., Connelly R.R., Easton J.M. Demographic patterns for nasopharyngeal carcinoma in the United States. Int J Cancer 1980, 26:741-748.
111. Burt R.D., Vaughan T.L., McKnight B. Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States. Int J Cancer 1992, 52:549-556.
112. Shi W., Pataki I., MacMillan C., et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002, 94:1997-2006.
113. Reddy S.P., Raslan W.F., Gooneratne S., Kathuria S., Marks J.E. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995, 16:103-108.
114. Wang Y., Zhang Y., Ma S. Racial differences in nasopharyngeal carcinoma in the United States. Cancer Epidemiol 2013, 37:793-802.
115. Richey L.M., Olshan A.F., George J., et al. Incidence and survival rates for young blacks with nasopharyngeal carcinoma in the United States. Arch Otolaryngol Head Neck Surg 2006, 132:1035-1040.
116. Bhattacharyya N. The impact of race on survival in nasopharyngeal carcinoma: a matched analysis. Am J Otolaryngol 2004, 25:94-97.
117. Ou S.H., Zell J.A., Ziogas A., Anton-Culver H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 2007, 18:29-35.
118. Su C.K., Wang C.C. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2002, 54:752-758.
119. Marks J.E., Phillips J.L., Menck H.R. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998, 83:582-588.
120. Lee A.W., Lau W.H., Tung S.Y., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005, 23:6966-6975.
121. Kwong D.L., Sham J.S., Au G.K., et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004, 22:2643-2653.
122. Liu M.T., Yeh C.Y. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Radiat Med 1998, 16:113-117.
123. Twu C.W., Wang W.Y., Liang W.M., et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007, 67:130-137.
124. Lin J.C., Wang W.Y., Chen K.Y., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470.
125. Lo Y.M., Chan A.T., Chan L.Y., et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000, 60:6878-6881.
126. Lee S.W., Nam S.Y., Im K.C., et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008, 87:211-216.
127. Yen T.C., Lin C.Y., Wang H.M., et al. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:1307-1314.
128. Liu T., Xu W., Yan W.L., Ye M., Bai Y.R., Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007, 85:327-335.
129. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
130. Chen L., Hu C.S., Chen X.Z., et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012, 13:163-171.
131. Cheng S.H., Jian J.J., Tsai S.Y., et al. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 1998, 41:755-762.
132. Cheng S.H., Jian J.J., Tsai S.Y., et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000, 48:1323-1330.
133. Malone J.P., Levin R.J. Second malignant tumors after treatment of nasopharyngeal carcinoma: four case reports and literature review. Skull Base 2002, 12:87-91.
134. Cooper J.S., Scott C., Marcial V., et al. The relationship of nasopharyngeal carcinomas and second independent malignancies based on the Radiation Therapy Oncology Group experience. Cancer 1991, 67:1673-1677.
135. Lee A.W., Law S.C., Ng S.H., et al. Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation. Br J Radiol 1992, 65:918-928.
136. Huang S.C. Nasopharyngeal cancer: a review of 1605 patients treated radically with cobalt 60. Int J Radiat Oncol Biol Phys 1980, 6:401-407.
137. Chan J.Y., Wong S.T., Lau G.I., Wei W.I. Postradiation sarcoma after radiotherapy for nasopharyngeal carcinoma. Laryngoscope 2012, 122:2695-2699.
138. Wang C.C., Chen M.L., Hsu K.H., et al. Second malignant tumors in patients with nasopharyngeal carcinoma and their association with Epstein-Barr virus. Int J Cancer 2000, 87:228-231.
139. Kong L., Lu J.J., Hu C., Guo X., Wu Y., Zhang Y. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer 2006, 107:1287-1293.
140. Chan J.Y., To V.S., Wong S.T., Wei W.I. Radiation-induced squamous cell carcinoma of the nasopharynx after radiotherapy for nasopharyngeal carcinoma. Head Neck 2014, 36:772-775.
141. Lo W.C., Ting L.L., Ko J.Y., et al. Malignancies of the ear in irradiated patients of nasopharyngeal carcinoma. Laryngoscope 2008, 118:2151-2155.
142. Lim L.H., Goh Y.H., Chan Y.M., Chong V.F., Low WK. Malignancy of the temporal bone and external auditory canal. Otolaryngol Head Neck Surg 2000, 122:882-886.
143. Nyrop M., Grontved A. Cancer of the external auditory canal. Arch Otolaryngol Head Neck Surg 2002, 128:834-837.
144. Lim L.H., Goh Y.H., Chan Y.M., Chong V.F., Low WK. Squamous cell carcinoma of the ear arising in patients after radiotherapy for nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2014, 271:149-156.
145. Williams E.H., de The G. Letter: familial aggregation in nasopharyngeal carcinoma. Lancet 1974, 2:295-296.
146. Jung P.F. Familial tendency of nasopharyngeal carcinoma; a report of cases. Pac Med Surg 1965, 73:242-243.
147. Jia W.H., Feng B.J., Xu Z.L., et al. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer 2004, 101:363-369.
148. Chen C.J., Liang K.Y., Chang Y.S., et al. Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency. Anticancer Res 1990, 10:547-553.
149. Zheng X., Yan L., Nilsson B., Eklund G., Drettner B. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol 1994, 33:867-872.
150. Lee H.P., Gourley L., Duffy S.W., Esteve J., Lee J., Day N.E. Preserved foods and nasopharyngeal carcinoma: a case-control study among Singapore Chinese. Int J Cancer 1994, 59:585-590.
151. Ng W.T., Choi C.W., Lee M.C., Chan S.H., Yau T.K., Lee AW. Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. Fam Cancer 2009, 8:103-108.
152. Ung A., Chen C.J., Levine P.H., et al. Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan. Anticancer Res 1999, 19:661-665.
153. Friborg J., Wohlfahrt J., Koch A., Storm H., Olsen O.R., Melbye M. Cancer susceptibility in nasopharyngeal carcinoma families-a population-based cohort study. Cancer Res 2005, 65:8567-8572.
154. Loh K.S., Goh B.C., Lu J., Hsieh W.S., Tan L. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg 2006, 132:82-85.
155. Ng W.T., Yau T.K., Yung R.W., et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005, 113:998-1001.
156. Zeng Y., Zhang L.G., Wu Y.C., et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985, 36:545-547.
157. Zong Y.S., Sham J.S., Ng M.H., et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992, 69:3-7.
158. Cheng W.M., Chan K.H., Chen H.L., et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002, 97:489-492.
159. Chien Y.C., Chen J.Y., Liu M.Y., et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001, 345:1877-1882.
160. Old L.J., Boyse E.A., Oettgen H.F., et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt[U+05F3]s lymphoma cells. Proc Natl Acad Sci U S A 1966, 56:1699-1704.
161. zur Hausen H., Schulte-Holthausen H., Klein G., et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970, 228:1056-1058.
162. Nonoyama M., Huang C.H., Pagano J.S., Klein G., Singh S. DNA of Epstein-Barr virus detected in tissue of Burkitt[U+05F3]s lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 1973, 70:3265-3268.
163. Wolf H., zur Hausen H., Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol 1973, 244:245-247.
164. Klein G., Giovanella B.C., Lindahl T., Fialkow P.J., Singh S., Stehlin JS., et al. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A 1974, 71:4737-4741.
165. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976, 17:1-7.
166. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002, 12:431-441.
167. Miller G., Niederman J.C., Andrews L.L. Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med 1973, 288:229-232.
168. Raab-Traub N., Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47:883-889.
169. Kripalani-Joshi S., Law H.Y. Identification of integrated Epstein-Barr virus in nasopharyngeal carcinoma using pulse field gel electrophoresis. Int J Cancer 1994, 56:187-192.
170. Niedobitek G., Hansmann M.L., Herbst H., et al. Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 1991, 165:17-24.
171. Vasef M.A., Ferlito A., Weiss L.M. Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus. Ann Otol Rhinol Laryngol 1997, 106:348-356.
172. Pathmanathan R., Prasad U., Chandrika G., Sadler R., Flynn K., Raab-Traub N., et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995, 146:1355-1367.
173. Raab-Traub N., Flynn K., Pearson G., et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 1987, 39:25-29.
174. Chen C.L., Wen W.N., Chen J.Y., Hsu M.M., Hsu H.C. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology 1993, 36:91-98.
175. Dickens P., Srivastava G., Loke S.L., Chan C.W., Liu Y.T. Epstein-Barr virus DNA in nasopharyngeal carcinomas from Chinese patients in Hong Kong. J Clin Pathol 1992, 45:396-397.
176. Gilligan K., Rajadurai P., Resnick L., Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci U S A 1990, 87:8790-8794.
177. Krueger G.R., Kottaridis S.D., Wolf H., Ablashi D.V., Sesterhenn K., Bertram G. Histological types of nasopharyngeal carcinoma as compared to EBV serology. Anticancer Res 1981, 1:187-194.
178. Pearson G.R., Weiland L.H., Neel H.B., et al. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983, 51:260-268.
179. Sam C.K., Prasad U., Pathmanathan R. Serological markers in the diagnosis of histopathological types of nasopharyngeal carcinoma. Eur J Surg Oncol 1989, 15:357-360.
180. Brooks L., Yao Q.Y., Rickinson A.B., Young L.S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992, 66:2689-2697.
181. Mainou B.A., Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006, 80:6458-6468.
182. Keryer-Bibens C., Pioche-Durieu C., Villemant C., et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006, 6:283.
183. Mei Y.P., Zhou J.M., Wang Y., et al. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 2007, 6:1379-1385.
184. Cao S.M., Liu Z., Jia W.H., et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One 2011, 6:e19100.
185. Zeng Y., Zhang L.G., Li H.Y., et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982, 29:139-141.
186. Neel H.B., Pearson G.R., Taylor W.F. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Ann Otol Rhinol Laryngol 1984, 93:477-482.
187. Han B.L., Xu X.Y., Zhang C.Z., et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev 2012, 13:2577-2581.
188. Chan K.C., Hung E.C., Woo J.K., et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 2013, 119:1838-1844.
189. Liu P., Fang X., Feng Z., et al. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. J Virol 2011, 85:11291-11299.
190. Shuda M., Feng H., Kwun H.J., et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A 2008, 105:16272-16277.
191. Lung M.L., Chang R.S., Huang M.L., et al. Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology 1990, 177:44-53.
192. Hu L.F., Zabarovsky E.R., Chen F., et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991, 72(Pt 10):2399-2409.
193. Lung M.L., Chang G.C., Miller T.R., Wara W.M., Phillips T.L. Genotypic analysis of Epstein-Barr virus isolates associated with nasopharyngeal carcinoma in Chinese immigrants to the United States. Int J Cancer 1994, 59:743-746.
194. Grunewald V., Bonnet M., Boutin S., et al. Amino-acid change in the Epstein-Barr-virus ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. Int J Cancer 1998, 75:497-503.
195. Sacaze C., Henry S., Icart J., Mariame B. Tissue specific distribution of Epstein-Barr virus (EBV) BZLF1 gene variants in nasopharyngeal carcinoma (NPC) bearing patients. Virus Res 2001, 81:133-142.
196. Dardari R., Khyatti M., Cordeiro P., et al. High frequency of latent membrane protein-1 30-bp deletion variant with specific single mutations in Epstein-Barr virus-associated nasopharyngeal carcinoma in Moroccan patients. Int J Cancer 2006, 118:1977-1983.
197. Chang K.P., Hao S.P., Lin S.Y., et al. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 2006, 116:541-546.
198. Nguyen-Van D., Ernberg I., Phan-Thi Phi P., Tran-Thi C., Hu L. Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1. Virus Genes 2008, 37:273-281.
199. See H.S., Yap Y.Y., Yip W.K., Seow H.F. Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia. World J Surg Oncol 2008, 6:18.
200. Busson P., Keryer C., Ooka T., Corbex M., et al. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 2004, 12:356-360.
201. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 1999, 261:79-95.
202. Gutierrez M.I., Spangler G., Kingma D., et al. Epstein-Barr virus in nasal lymphomas contains multiple ongoing mutations in the EBNA-1 gene. Blood 1998, 92:600-606.
203. Jing Y.Z., Wang Y., Jia Y.P., Luo B. Polymorphisms of Epstein-Barr virus BHRF1 gene, a homologue of bcl-2. Chin J Cancer 2010, 29:1000-1005.
204. Sung N.S., Edwards R.H., Seillier-Moiseiwitsch F., Perkins A.G., Zeng Y., Raab-Traub N. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer 1998, 76:207-215.
205. Zhang X.S., Wang H.H., Hu L.F., et al. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Lett 2004, 211:11-18.
206. Zhang X.S., Song K.H., Mai H.Q., et al. The 30-bp deletion variant: a polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China. Cancer Lett 2002, 176:65-73.
207. Young L.S., Yao Q.Y., Rooney C.M., et al. New type B isolates of Epstein-Barr virus from Burkitt[U+05F3]s lymphoma and from normal individuals in endemic areas. J Gen Virol 1987, 68(Pt 11):2853-2862.
208. Abdel-Hamid M., Chen J.J., Constantine N., Massoud M., Raab-Traub N. EBV strain variation: geographical distribution and relation to disease state. Virology 1992, 190:168-175.
209. Cheung S.T., Leung S.F., Lo K.W., et al. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. Int J Cancer 1998, 76:399-406.
210. Edwards R.H., Sitki-Green D., Moore D.T., Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol 2004, 78:868-881.
211. Li D.J., Bei J.X., Mai S.J., et al. The dominance of China 1 in the spectrum of Epstein-Barr virus strains from Cantonese patients with nasopharyngeal carcinoma. J Med Virol 2009, 81:1253-1260.
212. Miller W.E., Cheshire J.L., Baldwin A.S., Raab-Traub N. The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. Oncogene 1998, 16:1869-1877.
213. Johnson R.J., Stack M., Hazlewood S.A., et al. The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J Virol 1998, 72:4038-4048.
214. Kwok H., Wu C.W., Palser A.L., et al. Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J Virol 2014, 88:10662-10672.
215. Zeng M.S., Li D.J., Liu Q.L., et al. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 2005, 79:15323-15330.
216. Kwok H., Tong A.H., Lin C.H., et al. Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS One 2012, 7:e36939.
217. Singhi A.D., Stelow E.B., Mills S.E., Westra W.H. Lymphoepithelial-like carcinoma of the oropharynx: a morphologic variant of HPV-related head and neck carcinoma. Am J Surg Pathol 2010, 34:800-805.
218. Punwaney R., Brandwein M.S., Zhang D.Y., et al. Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Head Neck 1999, 21:21-29.
219. Rassekh C.H., Rady P.L., Arany I., et al. Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma. Laryngoscope 1998, 108:362-367.
220. Maxwell J.H., Kumar B., Feng F.Y., et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010, 32:562-567.
221. Lo E.J., Bell D., Woo J., et al. Human papillomavirus & WHO type I nasopharyngeal carcinoma. Laryngoscope 2010, 120(suppl 4):S185.
222. Mirzamani N., Salehian P., Farhadi M., Tehran E.A. Detection of EBV and HPV in nasopharyngeal carcinoma by in situ hybridization. Exp Mol Pathol 2006, 81:231-234.
223. Singhi A.D., Califano J., Westra W.H. High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck 2012, 34:213-218.
224. Dogan S., Hedberg M.L., Ferris R.L., Rath T.J., Assaad A.M., Chiosea S.I. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck 2014, 36:511-516.
225. Lin Z., Khong B., Kwok S., et al. Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients. Head Neck 2014, 36:709-714.
226. Huang C.C., Hsiao J.R., Yang M.W., et al. Human papilloma virus detection in neoplastic and non-neoplastic nasopharyngeal tissues in Taiwan. J Clin Pathol 2011, 64:571-577.
227. Robinson M., Suh Y.E., Paleri V., et al. Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infect Agent Cancer 2013, 8:30.
228. Stenmark M.H., McHugh J.B., Schipper M., et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 2014, 88:580-588.
229. Lo K.W., Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462.
230. Chow L.S., Lo K.W., Kwong J., et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 2004, 109:839-847.
231. Chen Y.J., Ko J.Y., Chen P.J., et al. Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 1999, 25:169-175.
232. Fan C.S., Wong N., Leung S.F., et al. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol 2000, 31:169-178.
233. Chien G., Yuen P.W., Kwong D., Kwong Y.L. Comparative genomic hybridization analysis of nasopharygeal carcinoma: consistent patterns of genetic aberrations and clinicopathological correlations. Cancer Genet Cytogenet 2001, 126:63-67.
234. Tsang Y.S., Lo K.W., Leung S.F., et al. Two distinct regions of deletion on chromosome 13q in primary nasopharyngeal carcinoma. Int J Cancer 1999, 83:305-308.
235. Hui A.B., Lo K.W., Teo P.M., Huang D.P. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 2002, 20:467-473.
236. Chow L.S., Lo K.W., Kwong J., Wong A.Y., Huang D.P. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 2004, 12:781-787.
237. Shao Y., Jiang H., Wu X., Luo Y., Tang W. p16 promoter hypermethylation is associated with increased risk of nasopharyngeal carcinoma. Mol Clin Oncol 2014, 2:1121-1124.
238. Lo K.W., Tsang Y.S., Kwong J., To K.F., Teo P.M., Huang D.P. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 2002, 98:651-655.
239. Krishna S.M., Kattoor J., Balaram P. Down regulation of adhesion protein E-cadherin in Epstein-Barr virus infected nasopharyngeal carcinomas. Cancer Biomark 2005, 1:271-277.
240. Zhou L., Jiang W., Ren C., et al. Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia 2005, 7:809-815.
241. Cheung C.C., Chung G.T., Lun S.W., et al. miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesis. Mol Cancer 2014, 13:184.
242. Leong J.L., Loh K.S., Putti T.C., Goh B.C., Tan L.K. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004, 114:153-157.
243. Ma B.B., Poon T.C., To K.F., et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003, 25:864-872.
244. Pan J., Kong L., Lin S., Chen G., Chen Q., Lu J.J. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008, 118:1970-1975.
245. Chua D.T., Nicholls J.M., Sham J.S., Au G.K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:11-20.
246. Tao Y., Song X., Deng X., et al. Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res 2005, 303:240-251.
247. Kung C.P., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol 2008, 82:5486-5493.
248. Thornburg N.J., Raab-Traub N. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes. J Virol 2007, 81:12954-12961.
249. Ma N., Kawanishi M., Hiraku Y., et al. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression. Int J Cancer 2008, 122:2517-2525.
250. Segawa Y., Oda Y., Yamamoto H., et al. Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. Oncol Rep 2009, 21:1197-1202.
251. Krishna S.M., James S., Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 2006, 115:85-90.
252. Li Y.H., Hu C.F., Shao Q., et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008, 6:1.
253. O'Neil J.D., Owen T.J., Wood V.H., et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 2008, 89:2833-2842.
254. Stevenson D., Charalambous C., Wilson J.B. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res 2005, 65:8826-8835.
255. Qian C.N., Guo X., Cao B., et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002, 62:589-596.
256. Horikawa T., Sheen T.S., Takeshita H., Sato H., Furukawa M., Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001, 159:27-33.
257. Lin D.C., Meng X., Hazawa M., et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet 2014, 46:866-871.
258. Chung G.T., Lung R.W., Hui A.B., et al. Identification of a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma. J Pathol 2013, 231:158-167.
259. Valouev A., Weng Z., Sweeney R.T., et al. Discovery of recurrent structural variants in nasopharyngeal carcinoma. Genome Res 2014, 24:300-309.